SEC Form 4 · accession 0001225208-18-002503
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maulik Nanavaty
Officer — SVP & Pres, Neuromodulation
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 9, 2018 | M | 15,568 | $12.52 | A | 229,757 | D | |
| Common StockF2,F1 | Feb 9, 2018 | S | 15,568 | $25.3798 | D | 214,189 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $12.52 | Feb 9, 2018 | M | 15,568 | D | — | Feb 12, 2018 | Common Stock | 15,568 | 0 | D |
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.392, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant.
Remarks
nanavatypoa.txt